EC approves Almirall's Skilarence for plaque psoriasis

The European Commission approved Skilarence (LAS41008) from Almirall S.A.(Madrid:ALM) to treat moderate to severe chronic plaque psoriasis, both for first-line induction and long-term maintenance treatment. Almirall plans to launch the drug next quarter in all EU member states, Iceland and Norway. The company declined to disclose a wholesale acquisition cost (WAC)...